发明名称 |
Hepatitis C virus inhibitors |
摘要 |
H:/ftintcnvoven/NRPortbl/DCC/FMT5O70377_3.DOC-12/04/2013 The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. |
申请公布号 |
AU2013204195(B2) |
申请公布日期 |
2016.09.22 |
申请号 |
AU20130204195 |
申请日期 |
2013.04.12 |
申请人 |
Enanta Pharmaceuticals, Inc. |
发明人 |
QIU, Yao-ling;WANG, Ce;PENG, Xiaowen;YING, Lu;OR, Yat Sun |
分类号 |
C07D401/14;A01N43/52 |
主分类号 |
C07D401/14 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|